The 2016
RNA Therapeutics conference will hone in on some key developments currently shaping the industry, and putting the spotlight on messenger
RNA-based Therapeutics.
We will review clinical trial updates in oncology, cardiovascular injury, and ophthalmology, and open the floor for discussion to review existing and emerging concepts in delivery systems, oligonucleotides, aptamer-conjugates as well as messenger
RNA therapeutics.The biggest challenge in enabling
RNAi therapy is transporting
RNA to target sites outside the liver, and so having targeted delivery systems, which can optimise bioavailability and controllable kinetics remains an issue. However, with exciting concepts such as polymeric nanoparticles and viral vectors as a new class of carriers existing on the horizon, the conference will look at the future of these technologies.
Moreover, messenger
RNA (mRNA) is attracting considerable interest for its ability to restore gene expression and correct protein production. Thus, we will anticipate what new avenues will open up in gene-based therapies.
New for 2016:
- Applications and delivery strategies for mRNA therapeutics
- Building your aptamer: Modifiable building blocks to enhance cell uptake and delivery
- Assessing pharmacokinetics and translation
- Upregulation of gene expression miRNA
Why you should Attend
- Discover exciting developments of mRNA-based therapeutics and delivery systems
- Discuss clinical developments and take away key lessons for future developments
- Understand the pharmacokinetic considerations of oligonucleotides and RNA therapies
- Learn and confront challenges affecting targeted delivery and overcoming biological barriers
Plus Two Interactive Half-Day Post- Conference Workshops | Wednesday 17th February 2016
Workshop A: Next generation aptamer-conjugated RNA delivery in precision medicineWorkshop Leaders: Dr. David Bunka, Chief Technical Officer, and
Edward Barnes, Research Scientist, Aptamer Group Ltd.
8.30am - 12.30pm
Workshop B: Strategies to optimize functional nanoparticlemediated delivery of RNAi effectors to target tissues then progress to clinical studiesWorkshop Leader: Prof Andrew David Miller, CSO, GlobalAcorn Ltd
12.30pm - 5.30pm
Speakers
- Andrew Miller, CSO, GlobalAcorn Ltd
- Ben Berkhout, Head of the Laboratory of Experimental Virology , University of Amsterdam
- Brian Kelly, Associate, Covington & Burling LLP
- C.I. Edvard Smith, Professor, Karolinska Institutet
- Christian Schetter, Chief Executive Office and Managing Director, Rigontec GmbH
- Christianne Rijcken, CSO, Cristal Therapeutics
- Claude Paul Malvy, Co-head of research group: Chemical Vectorology of anticancer drugs, Gustave Roussy Institute
- Covadonga Paneda, R&D Manager, Sylentis
- David Bunka, CEO, Aptamer group
- Heinrich Haas, VP RNA Formulation and Drug Developement, BioNTech AG
- James Legg, European and UK Patent Attorney, Boult Wade Tennant
- Juergen Soutschek, Consultant, Biotechnology
- Kai Wilkens, Senior Director Europe, Advanced Cell Diagnostics SRL
- Mustafa Diken, Deputy Vice President Immunotherapies and Preclinical Research, BioNTech AG
- Nagy Habib, Professor of Surgery, Chairman and Co-Founder, Imperial College London, MiNA Therapeutics
- Nigel Horscroft, Director, Alliance Management, CureVac
- Ryszard Kole, Distinguished Scientist, Sarepta Therapeutics
Please fill in your name and email to receive the conference agenda of this event.
The agenda is available as PDF under downloads at the right side of the page.
Venue
Holiday Inn Kensington Forum
97 Cromwell Rd, Kensington, SW7 4DN
London, UK
Venue
Holiday Inn Kensington Forum97 Cromwell Rd,
London, SW7 4DN
United Kingdom
